Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic barrier to the development of resistance to rilpivirine and etravirine between HIV-1 subtypes CRF02_AG and B.

The Journal of antimicrobial chemotherapy - 1 Nov 2013

Fofana D B, Soulie C, Maiga A I, Fourati S, Malet I, Wirden M, Tounkara A, Traore H A, Calvez V, Marcelin A G, Lambert-Niclot S

Abstract excerpt

OBJECTIVES: It has been demonstrated for some drugs that the genetic barrier, defined as the number of genetic transitions and/or transversions needed to produce a resistance mutation, can differ between HIV-1 subtypes. We aimed to assess differences in the genetic barrier for the evolution of resistance to the second-generation non-nucleoside reverse transcriptase inhibitors etravirine and rilpivirine in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Conserved Sequence

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to Nitriles

Share to Pyridazines

Share to Pyrimidines

Share to Rilpivirine

Source

Identifiers

PMID: 23833185
DOI: 10.1093/jac/dkt251

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic barrier to the development of resistance to rilpivirine and etravirine between HIV-1 subtypes CRF02_AG and B.PMID 23833185Read ↗

Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes.Semantic proximity Read ↗

The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes.Semantic proximity Read ↗

Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes.Semantic proximity Read ↗

Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.Semantic proximity Read ↗

Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy.Semantic proximity Read ↗

Genetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European Databank.Semantic proximity Read ↗

Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development.Semantic proximity Read ↗

Prevalence of etravirine resistance associated mutations in HIV-1 strains isolated from infected individuals failing efavirenz: comparison between subtype B and non-B genetic variants.Semantic proximity Read ↗

Nucleotide and amino acid polymorphisms at drug resistance sites in non-B-subtype variants of human immunodeficiency virus type 1.Semantic proximity Read ↗

The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors.Semantic proximity Read ↗

Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype B.Semantic proximity Read ↗

[Etravirine: genetic barrier and resistance development].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.